CoLucid Pharmaceuticals, which is working on a treatment for migraines, has secured backing from investors including Novo to take its total financing above the $100m mark.
CoLucid Pharmaceuticals, a US-based company developing a new treatment for migraines, has closed a $37.1m series C round yesterday which included Novo Ventures, the corporate venturing arm of healthcare company Novo Group.
The round was led by TVM Capital Life Science and also featured Auriga Partners, Pappas Ventures, Domain Associates, Care Capital, Triathlon Medical Ventures and Pearl Street Ventures. Novo, TVM and Auriga all participated as new investors.
The capital increased CoLucid’s total financing to approximately $104m in debt and…
